NEW YORK (Reuters Health) – Ambulatory telemetry can provide lifesaving information that is unavailable with other modalities, new research suggests. More than 26,000 patients with routine clinical indications…
NEW YORK (Reuters Health) – Adding pregabalin (Lyrica) to existing therapy for poorly controlled partial seizures reduces seizure frequency and is generally well tolerated over the long term,…
NEW YORK (Reuters Health) – Treatment with dutasteride reduces incident prostate cancers in men with high prostate specific antigen (PSA) levels, according to a report in The New…
NEW YORK (Reuters Health) – Sequential screening for type 2 diabetes is cost effective when started between the ages of 30 and 45 years and repeated every 3…
NEW YORK (Reuters Health) – Sunitinib and sorafenib significantly increase patients’ risk of arterial thromboembolic events, according to a report in the March 29th online issue of the…
NEW YORK (Reuters Health) – Patients starting clozapine must be monitored for endocarditis during the first month, particularly at week 3, new research shows. The researchers also suggest…
NEW YORK (Reuters Health) – To reduce the risk of adverse ischemic outcomes and death, angioplasty should be done within 24 hours of presentation for non-ST-segment elevation acute…
NEW YORK (Reuters Health) – If asymptomatic lower pole renal calculi require intervention, percutaneous nephrolithotomy will provide a higher stone-free rate than shock wave lithotripsy, and with less…
NEW YORK (Reuters Health) – Once-a-week treatment with long-acting exenatide (Byetta) produces sustained glycemic control and weight loss in diabetics, a multicenter trial has shown. “This study confirms…
NEW YORK (Reuters Health) – Sertraline plus naltrexone is more effective than either agent alone in promoting abstinence in depressed alcohol-dependent patients, according to study findings in the…